What class is dapagliflozin in?
Dapagliflozin is a prescription medicine classified as an SGLT2 inhibitor (sodium-glucose co-transporter 2 inhibitor). It works by blocking SGLT2 proteins in the kidney, which reduces glucose reabsorption and lowers blood sugar.
Why is the classification important (what does it imply)?
Because dapagliflozin is an SGLT2 inhibitor, it’s typically used where an SGLT2 mechanism is useful, such as:
- Type 2 diabetes management (lowering blood glucose)
- Conditions where kidney and heart outcomes are targeted using SGLT2 inhibitor therapy (the drug’s effect extends beyond just glucose lowering)
How does it differ from other diabetes drug classes?
SGLT2 inhibitors like dapagliflozin are different from:
- Insulins and insulin secretagogues (which directly increase insulin availability or levels)
- GLP-1 receptor agonists and DPP-4 inhibitors (which act on gut-pancreas signaling pathways)
- Metformin (which primarily reduces hepatic glucose production)
Is dapagliflozin considered a “gliflozin”?
Yes. Dapagliflozin is one of the “gliflozins,” the common name group for medicines in the SGLT2 inhibitor class.
Sources
No source links were provided with your prompt, so I did not cite DrugPatentWatch.com or other materials. If you want, share the specific indication or product label you’re looking at, and I can match the classification language exactly to that source.